Equities

Hetzer Medical Indonesia Tbk PT

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MEDS:JKT

Hetzer Medical Indonesia Tbk PT

Actions
Health CareMedical Equipment and Services
  • Price (IDR)78.00
  • Today's Change-1.00 / -1.27%
  • Shares traded11.30m
  • 1 Year change+56.00%
  • Beta1.0871
Data delayed at least 10 minutes, as of Feb 13 2026 09:13 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PT Hetzer Medical Indonesia Tbk is an Indonesia-based company, which is engaged in manufacturing medical devices. The Company's business products include medical devices, including variants of masks, stethoscopes, sphygmomanometers, and bouffant caps (head coverings/surgical caps) under the Evo Plusmed brand. Evo Plusmed manufactures masks with four-dimensional (4D) designs in Indonesia. The Company offers masks, such as Evo Plusmed 4D Sparks 4 Ply, Evo Plusmed 4D Colorful 3 Ply, Evo Plusmed 4D White 3 Ply, Evo Plusmed 4D Pon 4 Ply, Evo Plusmed 4D 5 Ply, Evo Plusmed 4D Hijab 3 Ply, Evo Mask for Kids among others. Its Sphygmomanometer products include Evo Plusmed Quantum Wall Aneroid, Evo Plusmed Quantum Mobile Aneroid, Evo Plusmed Quantum Desk Aneroid, and Evo Plusmed Colorful Aneroid. Its Stethoscope products include Evo Plusmed Cardiology Stethoscope, Evo Plusmed Classic Stethoscope, Evo Plusmed Stylo Stethoscope, and Evo Plusmed Colorful Stethoscope.

  • Revenue in IDR (TTM)4.95bn
  • Net income in IDR-8.74bn
  • Incorporated--
  • Employees16.00
  • Location
    Hetzer Medical Indonesia Tbk PTKompleks Blue Sky Industrial(BSI) Kav NCIMAHI 40532IndonesiaIDN
  • Phone+62 226679409
  • Fax+62 226613426
  • Websitehttps://www.evoplusmed.com/?lang=en
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Opto Circuits (India) Ltd202.40bn-238.68bn109.45bn1.84k------0.5408-4.27-4.273.83-------------14.78---30.0853.6252.13-126.79-151.05---0.7372-----29.10-31.34-2,762.41------
Hetzer Medical Indonesia Tbk PT4.95bn-8.74bn121.88bn16.00--2.39--24.61-5.59-5.593.1732.570.07580.56551.14275,078,000.00-13.3919.14-14.6922.4210.8965.16-176.5522.880.6321-16.360.1229---71.87-11.87-139.00---20.41--
Dosni Roha Indonesia Tbk PT940.81bn-315.87bn125.54bn1.31k--0.1145--0.1334-125.81-125.81374.72436.820.2961.151.37719,277,400.00-10.23-2.92-23.87-6.6219.1114.61-34.55-2.841.03-0.95170.4858---41.71149.99-18.87--79.26--
Pasture Holdings Ltd204.66bn9.10bn133.75bn25.0014.691.618.870.65360.00520.00520.11630.04711.082.8115.66613,991.904.828.298.8019.7827.9125.664.455.931.537.350.261---13.50-6.05-3.22-23.4520.11--
Dentas Co Ltd98.27bn429.17m134.28bn35.00----42.381.379.619.612,199.67-2.591.754.148.2022,863,590.001.01-3.313.25-6.0131.7330.050.578-2.320.6147-2.540.9278--6.1916.41165.10------
Mohini Health & Hygiene Ltd278.54bn-5.51bn135.54bn230.00--0.719436.980.4866-1.62-1.6282.1456.160.87983.264.836,516,165.00-1.74---2.63--24.67---1.98--1.15-1.350.2679---15.95---45.26------
Data as of Feb 13 2026. Currency figures normalised to Hetzer Medical Indonesia Tbk PT's reporting currency: Indonesian Rupiah IDR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.